Manufacturers at this stage have an opportunity to take a strategic look at how preliminary clinical trial results address the unmet need in the market and how this may influence reimbursement and access at launch. Xcenda recommends manufacturers take a proactive approach to evaluating the payer and reimbursement landscape, forecasting provider uptake, assessing product risk, and developing a health outcomes strategy.

Accelerate commercial opportunities with the following key services:

Analyze provider insights with Challenging Cases®

Take a prospective look at how patterns of care would change with the introduction of a new therapy. Forecast projected uptake by studying clinicians' response to clinical trial data.

Read More

Develop a risk management strategy

Review phase 2 or interim phase 3 trial results to prepare for anticipated REMS discussions with the FDA. Position your product for less-stringent requirements while still ensuring safe use.

Read More

Contract HEOR professionals

Access the HEOR experts you need to ramp up for launch. Flexible contract staff can develop data for field teams, design and implement a publication strategy, or support the ongoing development of the product value proposition—all in coordination with your internal stakeholders.

Read More

Later Development: Additional Services

  • Expand All
  • Collapse All
  • Gather payer insightsMore

  • Develop a managed markets strategyMore

  • Develop a compendia strategyMore